The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.

There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.

One or more techniques and/or systems are disclosed for a composition or formulation that can be used as a surface applied treatment for reducing odors, enhancing a user experience with pleasant scents, and mitigating skin irritation for items worn close to a user's skin. The composition can comprise a natural astringent, such as witch hazel. Further, the composition can comprise an essential oil, such as lavender, mint, tea tree, grapefruit, ylang ylang, eucalyptus, and vanilla, along with distilled water. These ingredient can be readily mixed together, and packaged in an appropriate container, such as a spray bottle. The composition can be applied to a target surface, such as the inside of a mask, by spraying applying the composition.

The invention relates to a compatible solute or a solute mixture, as well as to a composition comprising the solute or solute mixture, for use in the prevention or treatment of cosmetic or pathologic efflorescences caused by airborne particles, such as pigmentation accompanying with skin ageing, and de- or hypopigmentation, hyperpigmentation, as well as alterations accompanying with atrophy in the broadest sense. The solute or solute mixture, as well as the composition comprising the solute or solute mixture comprises at least one compound according to formula I, formula II, physiologically compatible salts of formula I and formula II, stereoisomeric forms of the compound of formula I, formula II, and physiologically compatible salts of the stereoisomeric forms, and the solute mixture comprises at least two of the afore-mentioned compounds, wherein in formula I

##STR00001##

and in formula II

##STR00002##

R1=H or alkyl; R2=H, COOH, COO-alkyl or CO—NH—R5; R3 and R4 each independently H or OH; R5=H, alkyl, an amino acid residue, dipeptide residue or tripeptide residue and n=1, 2 or 3 and alkyl corresponds to an alkyl group having C.sub.1-C.sub.4 carbon atoms.

Pharmaceutical, cosmetic and dietetic compositions and functional foods, constituted by: A) phospholipid mixtures containing N-acyl-phosphatidyl-ethanolamines (NAPEs) and/or B) phospholipid mixtures containing N-acyl-ethanol amines (NAEs) together with phosphatidic acids (PAs) and/or lysophosphatidic acids (LPAs) with the proviso that said N-acyl-phosphatidyl-ethanolamines (NAPEs) do not include N-oleoyl-phosphatidyl-ethanolamine. New phosphobioflavonic complexes of NAPE or NAE with one or more bioflavonoids are also disclosed.

Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

Disclosed is a cosmetic or pharmaceutical composition comprising a UV filter combination of (a) at least one benzotriazole derivative corresponding to the formula

##STR00001## wherein R.sub.1 is hydrogen; C.sub.1-C.sub.5alkyl; C.sub.1-C.sub.5alkoxy; or halogen; R.sub.2 is hydrogen; C.sub.1-C.sub.20alkyl; C.sub.1-C.sub.5alkoxy; C.sub.1-C.sub.5alkoxycarbonyl; C.sub.5-C.sub.10cycloalkyl; C.sub.5-C.sub.10aryl; or C.sub.5-C.sub.10aralkyl; R.sub.3 is C.sub.1-C.sub.20alkyl; C.sub.5-C.sub.10cycloalkyl; C.sub.1-C.sub.20alkoxy; or C.sub.5-C.sub.10cycloalkoxy; and R.sub.4 is hydrogen; or C.sub.1-C.sub.5alkyl; (b) at least one UV filter selected from (b.sub.1) benzylidene malonate UV filters; (b.sub.2) micronized 5,6,5′,6′-tetraphenyl-3,3′-(1,4-Phenylene)bis(1,2,4-Triazine) corresponding to the formula

##STR00002## (b.sub.3) Benzoic acid, 4,4′-[[6-[[3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]-1 disiloxanyl]propyl]amino]-1,3,5-triazine-2,4-diyl]diimino]bis-, dibutyl ester; and (b.sub.4) 2-Propenoic acid, 3-(4-methoxyphenyl)-, 2-methylphenyl ester; and optionally (c) at least one UV filter selected from (c.sub.1) Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine; (c.sub.2) Butyl Methoxydibenzoylmethane; (c.sub.3) Diethylhexyl Butamido Triazone; (c.sub.4) Ethylhexyl Triazone; (c.sub.5) Diethylamino Hydroxy Benzoyl Hexyl Benzoate; (c.sub.6) Ethylhexyl Methoxycinnamate; (c.sub.7) Ethylhexyl Salicylate; (c.sub.8) Homosalate; (c.sub.9) Octocrylene; (c.sub.10) Methylene Bis-Benzotriazolyl Tetramethylbutylphenol; (c.sub.11) Phenylbenzimidazole Sulfonic Acid; (c.sub.12) Titanium Dioxide; (c.sub.13) Tris-Biphenyl Triazine; (c.sub.14) (2-{4-[2-(4-Diethylamino-2-hydroxy-benzoyl)-benzoyl]-piperazine-1-carbonyl}-phenyl)-(4-diethylamino-2-hydroxy-phenyl)-methanone; (c.sub.15) merocyanine derivatives; (c.sub.16) Bis(butylbenzoate) diaminotriazine aminopropylsiloxane; and (c.sub.17) Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, encapsulated in a polymer matrix.

The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.

Compositions for transdermal delivery of an active agent and methods for using such compositions are described herein.